Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.51.3
PrivacidadTérminosCookiesAviso Legal
● Connected
BZYR US Equity
BURZYNSKI RESEARCH INSTITUTE INC
0.00USD
Healthcare
Biotechnology
96)Comparar97)Tesis →
Market Cap
$26,289.689
Shares Outstanding
131M
Revenue (TTM)
$0
Net Income (TTM)
−$1M
— Annual —FY2025
Revenue
$0
Book Value / Share
-0
BZYR US Equity
0.00USD
Tesis →

BURZYNSKI RESEARCH INSTITUTE INC (BZYR): análisis fundamental y valoración

BURZYNSKI RESEARCH INSTITUTE INC cotiza a 0.00 USD y tiene una capitalización bursátil de $26290. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaOTCPaísUnited StatesBeta0.43Web↗ propcitweb.ddns.net:83

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and o…

Múltiplos de Valoración
P/E (Annual)
—
P/E (TTM)
—
P/FCF (Annual)
—
P/FCF (TTM)
—
EV/EBITDA
—
EV/Revenue
—
P/Sales
—
P/Book
—
Rentabilidad (Último Anual)
Gross Margin
—
Operating Margin
—
Net Margin
—
FCF Margin
—
ROE
—
ROCE
—
ROA
-163660.8%
Effective Tax Rate
0.0%
Métricas TTM
Revenue TTM
$0
Gross Profit TTM
—
Operating Income TTM
−$1M
Net Income TTM
−$1M
FCF TTM
—
EPS TTM
-0.01
Quarters Used
4
TTM Period
2025-02-28 → 2025-11-30
Solidez del Balance
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Current Ratio
—
Interest Coverage
—
Working Capital
—
Book Value / Share
-0
Net Debt / Share
—
Crecimiento (YoY)
Revenue YoY
—
Net Income YoY
-3.8%
FCF YoY
—
EPS Diluted YoY
+0.0%
Retorno al Accionista
Dividend Yield
—
Payout Ratio
—
FCF / Share
—
CapEx % Revenue
—
Rev / Employee
—
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaBZYRMediana SectorΔ
Gross Margin—57.0%—
Operating Margin—-38.6%—
Net Margin—-33.6%—
FCF Margin—-13.9%—
ROE—-40.4%—
ROA-163660.8%-32.0%-163628.8%
Current Ratio—2.84—
Debt / Equity—0.28—
Scoring Fundamental
Capital Allocation
1/ 8Débil
✗FCF+Free cash flow positivo
✗FCFmMargen FCF > 10%
✓DilucSin dilución significativa (< 2%/año en 3 años)
✗Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✗DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✗Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)